Pain Therapeutics, Inc. Stock Nasdaq
Equities
US69562K1007
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
04-29 | North American Morning Briefing : Investors Brace -2- | DJ |
03-25 | Cassava Sciences Announces Completion of Interim Safety Review for Alzheimer's Drug Candidate Simufilam | MT |
Sales 2024 * | - | Sales 2025 * | 150M 205M | Capitalization | 954M 1.3B |
---|---|---|---|---|---|
Net income 2024 * | -96M -131M | Net income 2025 * | - 0 | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 6.36 x |
P/E ratio 2024 * |
-10.3
x | P/E ratio 2025 * |
-46.4
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.82% |
Managers | Title | Age | Since |
---|---|---|---|
Remi Barbier
CEO | Chief Executive Officer | 64 | 98-04-30 |
Eric Schoen
DFI | Director of Finance/CFO | 55 | 18-09-30 |
James Kupiec
CTO | Chief Tech/Sci/R&D Officer | - | 21-01-03 |
Members of the board | Title | Age | Since |
---|---|---|---|
Remi Barbier
CEO | Chief Executive Officer | 64 | 98-04-30 |
Robert Gussin
BRD | Director/Board Member | 86 | 03-02-28 |
Patrick Scannon
BRD | Director/Board Member | 76 | 07-12-06 |
1st Jan change | Capi. | |
---|---|---|
-1.65% | 104B | |
+6.75% | 97.47B | |
+5.71% | 22.25B | |
-12.60% | 21.68B | |
-9.70% | 18.2B | |
-39.98% | 17.02B | |
-10.17% | 16.36B | |
+6.12% | 14.39B | |
+35.47% | 12.37B |